Welcome to our dedicated page for COGNITION THERAPEUTICS news (Ticker: CGTX), a resource for investors and traders seeking the latest updates and insights on COGNITION THERAPEUTICS stock.
Cognition Therapeutics, Inc. develops clinical-stage drug candidates for neurodegenerative disorders, with news centered on zervimesine (CT1812), an investigational oral small molecule designed to protect neuronal synapses from toxic protein oligomers. Company updates commonly address dementia with Lewy bodies, Alzheimer’s disease, mild cognitive impairment, and geographic atrophy secondary to dry AMD.
Recurring developments include Phase 2 study data from programs such as SHIMMER and START, regulatory interactions with U.S. and European agencies, scientific conference presentations, expanded access activity, and quarterly financial results. News also covers NIH-related grant funding, cash runway commentary, and clinical-development plans tied to zervimesine’s use across central nervous system and retina indications.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced the appointment of Ellen B. Richstone to its board of directors, where she will chair the audit committee. Richstone brings extensive experience from Fortune 500 companies and board positions in manufacturing and technology. Her leadership in finance, operations, and over 35 acquisitions, totaling $1 billion raised, positions her to enhance Cognition's strategic direction. Richstone's academic credentials include degrees from Scripps College and Tufts University, and she has been recognized for her governance contributions.
Pittsburgh Life Science Greenhouse (PLSG) announced that its portfolio company, Cognition Therapeutics, Inc., launched an initial public offering (IPO) on October 8, 2021, trading under the ticker symbol CGTX. The IPO is expected to generate approximately $45.2 million in gross proceeds. Cognition Therapeutics focuses on developing oral drug candidates for neurodegenerative disorders, including Alzheimer's disease, with its lead candidate CT1812 currently in clinical trials. Proceeds from the IPO will be reinvested to support other life sciences startups in the region.
Cognition Therapeutics has announced the pricing of its upsized initial public offering (IPO) of 3,768,116 shares at a public offering price of $12.00 per share, aiming for gross proceeds of approximately $45.2 million. The shares will begin trading on the Nasdaq Global Market under the ticker symbol CGTX on October 8, 2021, with the offering expected to close on October 13, 2021.
B. Riley Securities, Inc. is the lead bookrunning manager for this offering.
Cognition Therapeutics, a clinical-stage biopharmaceutical company, has launched an initial public offering of 3,350,000 shares of common stock, with an anticipated price range of $11.00 to $13.00 per share. The company has also granted underwriters a 45-day option to purchase an additional 502,500 shares. The offering is subject to market conditions and follows an SEC registration statement that has yet to become effective. Cognition's stock is set to trade on Nasdaq under the symbol CGTX.